P. D. Schneider, R. A. Wise, M. C. Hochberg and F. M. Wigley, “Serial Pulmonary Function in Systemic Sclerosis,” American Journal of Medicine, Vol. 73, No. 3, 1982, pp. 385-394. http://dx.doi.org/10.1016/0002-9343(82)90732-X
 D. P. Tashkin, R. Elashoff, P. J. Clements, J. Goldin, M. D. Roth, D. E. Furst, et al., “Cyclophosphamide versus Placebo in Scleroderma Lung Disease,” New England Journal of Medicine, Vol. 354, No. 25, 2006, pp. 2655-2666. http://dx.doi.org/10.1056/NEJMoa055120
 D. P. Tashkin, R. Elashoff, P. J. Clements, M. D. Roth, D. E. Furst, R. M. Silver, et al., “Effects of 1-Year Treatment with Cyclophosphamide on Outcomes at 2 Years in Scleroderma Lung Disease,” American Journal of Respiratory and Critical Care Medicine, Vol. 176, No. 10, 2007, pp. 1026-1034. http://dx.doi.org/10.1164/rccm.200702-326OC
 R. K. Hoyles, R. W. Ellis, J. Wellsbury, B. Lees, P. Newlands, N. S. Goh, et al., “A Multicenter, Prospective, Randomized, Double-Blind, Placebo-Controlled Trial of Corticosteroids and Intravenous Cyclophosphamide Followed by Oral Azathioprine for the Treatment of Pulmonary Fibrosis in Scleroderma,” Arthritis & Rheumatology, Vol. 54, No. 12, 2006, pp. 3962-3970. http://dx.doi.org/10.1002/art.22204
 J. Madsen, A. Kliem, I. Tornoe, K. Skjodt, C. Koch and U. Holmskov, “Localization of Lung Surfactant Protein D on Mucosal Surfaces in Human Tissues,” Journal of Immunology, Vol. 164, No. 11, 2000, pp. 5866-5870.
 Y. Asano, H. Ihn, K. Yamane, N. Yazawa, M. Kubo, M. Fujimoto, et al., “Clinical Significance of Surfactant Protein D as a Serum Marker for Evaluating Pulmonary Fibrosis in Patients with Systemic Sclerosis,” Arthritis & Rheumatology, Vol. 44, No. 6, 2001, pp. 1363-1369. http://dx.doi.org/10.1002/1529-0131(200106)44:6<1363::AID-ART229>3.0.CO;2-5
 K. Yanaba, M. Hasegawa, K. Takehara and S. Sato, “Comparative Study of Serum Surfactant Protein-D and KL-6 Concentrations in Patients with Systemic Sclerosis as Markers for Monitoring the Activity of Pulmonary Fibrosis,” Journal of Rheumatology, Vol. 31, No. 6, 2004, pp. 1112-1120.
 K. Yamane, H. Ihn, M. Kubo, N. Yazawa, K. Kikuchi, Y. Soma and K. Tamaki, “Serum Levels of KL-6 as a Useful Marker for Evaluating Pulmonary Fibrosis in Patients with Systemic Sclerosis,” Journal of Rheumatology, Vol. 27, No. 4, 2000, pp. 930-934.
 K. Yanaba, M. Hasegawa, Y. Hamaguchi, M. Fujimoto, K. Takehara and S. Sato, “Longitudinal Analysis of Serum KL-6 Levels in Patients with Systemic Sclerosis: Association with the Activity of Pulmonary Fibrosis,” Clinical and Experimental Rheumatology, Vol. 21, No. 4, 2003, pp. 429-436.
 F. N. Hant, A. Ludwicka-Bradley, H. J. Wang, N. Li, R. Elashoff, D. P. Tashkin, et al., “Surfactant Protein D and KL-6 as Serum Biomarkers of Interstitial Lung Disease in Patients with Scleroderma,” Journal of Rheumatology, Vol. 36, No. 4, 2009, pp. 773-780. http://dx.doi.org/10.3899/jrheum.080633
 S. Sato, T. Nagaoka, M. Hasegawa, C. Nishijima and K. Takehara, “Elevated Serum KL-6 Levels in Patients with Systemic Sclerosis: Association with the Severity of Pulmonary Fibrosis,” Dermatology, Vol. 200, No. 3, 2000, pp. 196-201. http://dx.doi.org/10.1159/000018382
 Preliminary Criteria for the Classification of Systemic Sclerosis (Scleroderma), “Subcommittee for Scleroderma criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee,” Arthritis & Rheumatology, Vol. 23, No. 5, 1980, pp. 581-590.
 E. C. LeRoy, C. Black, R. Fleischmajer, S. Jablonska, T. Krieg, T. A. Medsger Jr., et al., “Scleroderma (Systemic Sclerosis): Classification, Subsets and Pathogenesis,” Jour- nal of Rheumatology, Vol. 15, No. 2, 1988, pp. 202-205.
 A. Yokoyama, K. Kondo, M. Nakajima, T. Matsushima, T. Takahashi, M. Nishimura, et al., “Prognostic Value of Circulating KL-6 in Idiopathic Pulmonary Fibrosis,” Respirology, Vol. 11, No. 2, 2006, pp. 164-168. http://dx.doi.org/10.1111/j.1440-1843.2006.00834.x
 N. S. Goh, S. R. Desai, S. Veeraraghavan, D. M. Hansell, S. J. Copley, T. M. Maher, et al., “Interstitial Lung Disease in Systemic Sclerosis: A Simple Staging System,” American Journal of Respiratory and Critical Care Medicine, Vol. 177, No. 11, 2008, pp. 1248-1254. http://dx.doi.org/10.1164/rccm.200706-877OC
 S. Assassi, R. Sharif, R. E. Lasky, T. A. McNearney, Y. M. R. M. Estrada, H. Draeger, et al., “Predictors of Interstitial Lung Disease in Early Systemic Sclerosis: A Prospective Longitudinal Study of the GENISOS Cohort,” Arthritis Research & Therapy, Vol. 12, No. 5, 2010, p. R166. http://dx.doi.org/10.1186/ar3125
 V. D. Steen, C. Conte, G. R. Owens and T. A. Medsger Jr., “Severe Restrictive Lung Disease in Systemic Sclerosis,” Arthritis & Rheumatology, Vol. 37, No. 9, 1994, pp. 1283-1289. http://dx.doi.org/10.1002/art.1780370903
 D. P. Tashkin, P. J. Clements, R. S. Wright, H. Gong Jr., M. S. Simmons, P. A. Lachenbruch, et al., “Interrelationships between Pulmonary and Extrapulmonary Involvement in Systemic Sclerosis. A Longitudinal Analysis,” Chest, Vol. 105, No. 2, 1994, pp. 489-495. http://dx.doi.org/10.1378/chest.105.2.489
 G. Kumanovics, T. Minier, J. Radics, L. Palinkas, T. Berki and L. Czirjak, “Comprehensive Investigation of Novel Serum Markers of Pulmonary Fibrosis Associated with Systemic Sclerosis and Dermato/Polymyositis,” Clinical and Experimental Rheumatology, Vol. 26, No. 3, 2008, pp. 414-420.
 J. E. Cotes, D. J. Chinn and M. R. Miller, “Lung Function: Physiology, Measurement, and Application in Medicine,” 6th Edition, Blackwell Publishing, 2006. http://dx.doi.org/10.1002/9781444312829
 H. I. Goldman and M. R. Becklake, “Respiratory Function Tests; Normal Values at Median Altitudes and the Prediction of Normal Results,” American Review of Tuberculosis, Vol. 79, No. 4, 1959, pp. 457-467.